|
Interagency Task Force on the Arts and Human Development
|
Committee, Work group, Advisory group, or Task Force
|
ACF, CDC, SAMHSA
|
NICHD, NCCIH, NCI, NIA, NIMH, OD/DPCPSI/OBSSR
|
Beginning in 2011, the National Endowment for the Arts (NEA) has convened a Federal Interagency Task Force on the Arts and Human Development to encourage more and better research on how the arts can help people reach their full potential at all stages of life.
|
|
Interagency Task Force on Trauma-Informed Care
|
Committee, Work group, Advisory group, or Task Force
|
ACF, AHRQ, CDC, FDA, HRSA, IHS, OS, SAMHSA
|
NIMH, NICHD
|
The Interagency Task Force on Trauma-Informed Care (TIC Task Force) was established under Public Law 115-271, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act of 2018. The TIC Task Force is charged to identify, evaluate, and make recommendations regarding: (1) best practices with respect to children and youth, and their families as appropriate, who have experienced or are at risk of experiencing trauma; and (2) ways in which Federal agencies can better coordinate to improve the Federal response to families impacted by substance use disorders and other forms of trauma.
|
|
Interagency Workgroup on Coordinating Opportunities for Evaluating Dolutegravir and Neural Tube Defects Association
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NICHD
|
This is a group addressing the potential association of dolutegravir and neural tube defects and associated research and policy issues.
|
|
Interagency Workgroup on Technology to Facilitate Aging in Place
|
Research Initiative
|
ACL, CMS, FDA
|
NIA, NCI, NHLBI, NIBIB, NINDS, NINR
|
The purpose of this Trans-National Institutes of Health (NIH) Inter-Agency group is to develop new platforms for everyday life technology that will enhance the common goals of multiple NIH institutes and other federal government agencies by improving the capability to rapidly conduct peer-reviewed technology research to facilitate aging in place, with a special emphasis on people from underrepresented groups. A platform is a group of technologies that are used as a base upon which other applications, processes or technologies are developed.
|
|
Interagency Working Group in the Glycosciences
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIGMS, NCI, NICHD, NIDCR, NIDDK
|
This group meets annually to identify synergies, discuss progress on the development of national standards for carbohydrates, and exchange information on the glycosciences being pursued at each agency
|
|
Interagency working group on Biological Data Sharing
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIGMS, NCI
|
The working group will identify the diverse types of biological and clinical data, define specific needs and best practices for storing, managing, curating, archiving, and maintaining the confidentiality and integrity of these data, and define agency roles and responsibilities for addressing research and policy (exclusive of regulatory) priority gaps to enable data sharing. The working group will develop a road map to enable robust sharing and maximize reuse of data, identifying opportunities for interagency coordination, and academic, industrial, and international partnerships.
|
|
Interdepartmental Health Equity Collaborative (formerly FIHET)
|
Committee, Work group, Advisory group, or Task Force
|
ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA
|
NIMHD, NCATS, NCI, NHLBI, NIA, NIAAA, NIAID, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIMH, NINR, OD/DPCPSI/ODP
|
Federal leadership for the National Partnership for Action to End Health Disparities (NPA) is provided by the Interdepartmental Health Equity Collaborative (IHEC). The IHEC was established to foster communications and activities of the NPA within federal agencies and their partners; and to increase the efficiencies and effectiveness of related policies and programs at the national, state, tribal, and local levels.
|
|
Interdepartmental Serious Mental Illness Coordinating Committee (ISMICC)
|
Committee, Work group, Advisory group, or Task Force
|
CMS, SAMHSA
|
NIMH
|
In December 2016, the 21st Century Cures Act was signed into law (Public Law 114‐255). Through this Act, the Interdepartmental Serious Mental Illness Coordinating Committee (ISMICC) was established to address the needs of adults with serious mental illness (SMI) and children and youth with serious emotional disturbance (SED) and their families. The Assistant Secretary for Mental Health and Substance Use and other federal members of the ISMICC works across the Department of Health and Human Services (HHS) and other federal departments so that Americans with SMI and SED are able to improve their lives and receive the highest possible standard of care—care that is deeply informed by knowledge of science and medicine. The ISMICC includes representatives from eight federal departments that support programs that address the needs of people with SMI and SED, and is informed and strengthened by the participation of non‐federal members, including national experts on health care research, mental health providers, advocates, people with living with mental health conditions, and their families and caregivers. This cross‐sector, public‐private partnership provides a unique opportunity to share and generate solutions to the problems facing the mental health system. The ISMICC seeks to support a system where individuals with SMI or SED are able to engage effectively with a range of treatment and recovery support services that promote opportunities for people to live well in their communities. A central charge of this committee is to submit two reports to Congress, the first no later than one year after the enactment of the Act, and the second five years following enactment. The ISMICC has five priority areas and corresponding workgroups for these priority areas. Representatives from NIMH sit on each of these workgroups.
|
|
Interdepartmental Substance Use Disorders Coordinating Committee (ISUDCC)
|
Committee, Work group, Advisory group, or Task Force
|
SAMHSA
|
NIDA
|
The Secretary of Health and Human Services, in coordination with the Director of the Office of National Drug Control Policy, is required by the SUPPORT for Patients and Communities Act Public Law 115-271 (PDF | 679 KB) to establish an Interdepartmental Substance Use Disorders Coordinating Committee composed of federal and non-federal members to accomplish the following duties:
1. Identify areas for improved coordination of activities, if any, related to substance use disorders, including research, services, supports, and prevention activities across all relevant federal agencies;
2. Identify and provide to the Secretary recommendations for improving federal programs for the prevention and treatment of, and recovery from, substance use disorders, including by expanding access to prevention, treatment, and recovery services;
3. Analyze substance use disorder prevention and treatment strategies in different regions of and populations in the United States and evaluate the extent to which federal substance use disorder prevention and treatment strategies are aligned with State and local substance use disorder prevention and treatment strategies;
4. Make recommendations to the Secretary regarding any appropriate changes with respect to the activities and strategies described in items (1) through (3) above;
5. Make recommendations to the Secretary regarding public participation in decisions relating to substance use disorders and the process by which public feedback can be better integrated into such decisions; and
6. Make recommendations to ensure that substance use disorder research, services, supports, and prevention activities of the Department of Health and Human Services and other federal agencies are not unnecessarily duplicative.
|
|
Interferon Lambda (IFN-?): Disease Impact and Therapeutic Potential
|
Meeting/ Workshop
|
FDA
|
NCI, NIAID, NIDDK
|
Scientists from the National Cancer Institute (NCI) and Food and Drug Administration (FDA) collaborated to organize a meeting that was held at the National Institutes of Health (NIH) on October 25-26, 2018. The purpose of the meeting was to promote research on IFN-λs by enhancing interdisciplinary communication.
|